Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2021
2020
2019
Profitability Metrics
Gross Margin
47.67%
Operating Margin
-78.69%
Net Margin
-60.99%
Efficiency Metrics
Revenue per Expense Ratio
1.00
R&D as % of Revenue
0.00%
Earnings Quality
EBITDA Margin
-22.59%
Income Tax Rate
0.00%
EPS
-9.7100000000
Balance Sheet Analysis
Current Ratio
0.90
Cash Ratio
0.26
Working Capital
$-86.68M
Debt to Equity
1.12
Debt to Assets
46.42%
Equity Ratio
41.47%
Cash Flow Analysis
Operating Cash Flow Ratio
25.12%
Free Cash Flow Ratio
-3.30%
CapEx to Revenue
28.42%
Dividends Paid
$230.93M
Stock Buybacks
$20.78M
Total Shareholder Returns
$251.71M
Cash Position Change
-12.64%
Key Takeaways (2023 FY)
Increased R&D investment by 100.00%
Detailed Growth Metrics
Core Performance
Revenue
10.52%
Net Income
-236.18%
EPS
-274.90%
Operating Income
-738.43%
Operational Efficiency
R&D Expenses
100.00%
SG&A Expenses
18.75%
Operating Cash Flow
-16.87%
Free Cash Flow
1,029.84%
Balance Sheet Health
Assets
-22.86%
Debt
-32.06%
Book Value per Share
-16.24%
Inventory
100.00%
Shareholder Returns
Dividends per Share
-11.76%
Shares Outstanding
-0.17%
Long Term Trends
3Y Revenue/Share
-6.96%
5Y Revenue/Share
0.97%
3Y Dividend/Share
-15.80%
5Y Dividend/Share
0.00%